HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Randolph, R.K. Articles by Cheronis, J. Search for Related Content PubMed PubMed Citation Articles by Randolph, R.K. Articles by Cheronis, J.

---

ORIGINAL RESEARCH ARTICLE

Regulation of Human Immune Gene Expression as Influenced by a Commercial Blended Echinacea Product: Preliminary Studies

R.K. Randolph^*,1, K. Gellenbeck^*, K. Stonebrook^*, E. Brovelli^*, Y. Qian^*, D. Bankaitis-Davis and J. Cheronis

^* Nutrilite Health Institute, Access Business Group, LLC, Buena Park, California 90622 and
Source Precision Medicine, Boulder, Colorado 80301

Consumption of Echinacea at the first sign of symptoms has been clinically shown to reduce both the severity and duration of cold and flu. Quantitative polymerase chain reaction optimized for precision and reproducibility was utilized to explore in vitro and in vivo changes in the expression of immunomodulatory genes in response to Echinacea. In vitro exposure of THP-1 cells to 250 µg/ml of Echinacea species extracts induced expression (up to 10-fold) of the interleukin-1, interleukin-1ß, tumor necrosis factor-, intracellular adhesion molecule, interleukin-8, and interleukin-10 genes. This preliminary result is consistent with a general immune response and activation of the nonspecific immune response cytokines.

In vivo gene expression within peripheral leukocytes was evaluated in six healthy nonsmoking subjects (18–65 years of age). Blood samples were obtained at baseline and on Days 2, 3, 5, and 12 after consuming a commercial blended Echinacea product, three tablets three times daily (1518 mg/day) for two days plus one additional dose (506 mg) on day three. Serum chemistry and hematological values were not different from baseline, suggesting that liver or bone marrow responses were not involved in acute responses to Echinacea. The overall gene expression pattern at 48 hr to 12 days after taking Echinacea was consistent with an antiinflammatory response. The expression of interleukin-1ß, tumor necrosis factor-, intracellular adhesion molecule, and interleukin–8 was modestly decreased up through Day 5, returning to baseline by day 12. The expression of interferon- steadily rose through Day 12, consistent with an antiviral response. These preliminary data present a gene expression response pattern that is consistent with Echinacea’s reported ability to reduce both the duration and intensity of cold and flu symptoms.

Key Words: THP-1 cells • interleukin-1 • interferon-alpha • cichoric acid • quantitative PCR • dietary supplement

This article has been cited by other articles:

				S. Raduner, A. Majewska, J.-Z. Chen, X.-Q. Xie, J. Hamon, B. Faller, K.-H. Altmann, and J. Gertsch Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS J. Biol. Chem., May 19, 2006; 281(20): 14192 - 14206. [Abstract] [Full Text] [PDF]

				J. A. Olalde Rangel, M. Magarici, F. Amendola, and O. del Castillo The Systemic Theory of Living Systems. Part IV: Systemic Medicine--The Praxis Evid. Based Complement. Altern. Med., December 1, 2005; 2(4): 429 - 439. [Abstract] [Full Text] [PDF]